Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pigment epithelium-derived factor engineered to increase glycosaminoglycan affinity while maintaining bioactivity.

Biochemical and biophysical research communications·2022
Same author

Laboratory Abnormalities in Pregnant Women with Novel Coronavirus Disease 2019.

American journal of perinatology·2020
Same author

Influence of Ward Environments on External Ventricular Drain Infections: A Retrospective Risk Factor Analysis.

Surgical infections·2020
Same author

Genomic analysis and clinical implications of immune cell infiltration in gastric cancer.

Bioscience reports·2020
Same author

Enhanced recovery after surgery protocols in patients undergoing liver transplantation: A retrospective comparative cohort study.

International journal of surgery (London, England)·2020
Same author

Activator of thyroid and retinoid receptor increases sorafenib resistance in hepatocellular carcinoma by facilitating the Warburg effect.

Cancer science·2020
Same journal

Analysis of strength degradation of coal and rock masses and stability of mined areas under long term immersion environment.

PloS one·2026
Same journal

Biogenic Silver-Selenium nanocomposite with anticancer activity and potent efficacy against vancomycin-resistant Staphylococcus aureus.

PloS one·2026
Same journal

Preparation and physicochemical characterization of a biodegradable chitosan/carboxymethyl cellulose hydrogel synthesized in NaOH/urea medium.

PloS one·2026
Same journal

Action-guilt, survivor-guilt, and depression in combat-related PTSD.

PloS one·2026
Same journal

Explainable machine learning for predicting activities of daily living at discharge in stroke patients: A retrospective study using SHAP interpretability.

PloS one·2026
Same journal

Deep learning based two-way feature depiction model for brain tumor detection.

PloS one·2026
See all related articles

Related Experiment Video

Updated: Jun 12, 2026

Polyelectrolyte Complex for Heparin Binding Domain Osteogenic Growth Factor Delivery
12:27

Polyelectrolyte Complex for Heparin Binding Domain Osteogenic Growth Factor Delivery

Published on: August 22, 2016

Control growth factor release using a self-assembled [polycation:heparin] complex.

Blaine J Zern1, Hunghao Chu, Yadong Wang

  • 1Wallace H. Coulter Department of Biomedical Engineering, School of Chemistry and Biochemistry, and Institute for Bioengineering and Biosciences, Georgia Institute of Technology, Atlanta, Georgia, USA.

Plos One
|June 15, 2010
PubMed
Summary
This summary is machine-generated.

Researchers developed a new method using heparin to control the release of fibroblast growth factor-2 (FGF-2). This biomaterial platform enhances growth factor stability and bioactivity for potential medical applications.

More Related Videos

Composite Scaffolds of Interfacial Polyelectrolyte Fibers for Temporally Controlled Release of Biomolecules
11:13

Composite Scaffolds of Interfacial Polyelectrolyte Fibers for Temporally Controlled Release of Biomolecules

Published on: August 19, 2015

Related Experiment Videos

Last Updated: Jun 12, 2026

Polyelectrolyte Complex for Heparin Binding Domain Osteogenic Growth Factor Delivery
12:27

Polyelectrolyte Complex for Heparin Binding Domain Osteogenic Growth Factor Delivery

Published on: August 22, 2016

Composite Scaffolds of Interfacial Polyelectrolyte Fibers for Temporally Controlled Release of Biomolecules
11:13

Composite Scaffolds of Interfacial Polyelectrolyte Fibers for Temporally Controlled Release of Biomolecules

Published on: August 19, 2015

Area of Science:

  • Biomaterials Science
  • Biochemistry
  • Regenerative Medicine

Background:

  • Growth factors are crucial in medicine but have short plasma half-lives, limiting their efficacy.
  • Sulfated glycosaminoglycans, like heparin, naturally protect and stabilize growth factors in vivo.
  • Existing methods for growth factor delivery often face challenges with stability and controlled release.

Purpose of the Study:

  • To investigate heparin as a stabilizing agent for controlled release of fibroblast growth factor-2 (FGF-2).
  • To develop a novel delivery platform for heparin-binding growth factors using a biocompatible polycation.
  • To assess the bioactivity and cellular response of FGF-2 released from the engineered matrix.

Main Methods:

  • Formation of a [heparin:FGF-2] complex precipitated by a biocompatible polycation.
  • Development of a release matrix from the precipitated complex.
  • Modulation of FGF-2 release rates by altering polycation molecular weight.
  • Assessment of released FGF-2 bioactivity and cellular response in vitro.

Main Results:

  • A stable release matrix for FGF-2 was successfully created using heparin and a polycation.
  • The release rate of FGF-2 could be precisely controlled by adjusting the polycation's molecular weight.
  • Released FGF-2 demonstrated maintained bioactivity, eliciting cellular responses comparable to fresh FGF-2.

Conclusions:

  • A novel, controllable drug delivery platform for FGF-2 has been developed.
  • This platform leverages heparin's binding properties for enhanced growth factor stability and efficacy.
  • The technology is adaptable for a wide range of heparin-binding growth factors, indicating broad therapeutic potential.